Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
07 mars 2024 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
04 mars 2024 16h01 HE
|
Cara Therapeutics, Inc.
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
12 févr. 2024 16h01 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at...
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
22 janv. 2024 07h00 HE
|
Cara Therapeutics, Inc.
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – –...
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
18 déc. 2023 07h00 HE
|
Cara Therapeutics, Inc.
– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in...
Cara Therapeutics Reports Third Quarter 2023 Financial Results
13 nov. 2023 16h01 HE
|
Cara Therapeutics, Inc.
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical...
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
02 nov. 2023 07h00 HE
|
Cara Therapeutics, Inc.
Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) --...
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
23 oct. 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
25 sept. 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...